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Abstract 
Brain volume loss (BVL) has gained increasing interest for monitoring tissue damage in 
neurodegenerative diseases including multiple sclerosis (MS). In this longitudinal study 117 healthy 
participants (age range 37.3–82.6 years) received at least 2 magnetic resonance imaging examinations. 
BVL (in %) was determined with SIENA/FSL and annualized. Mean BVL per year was 0.15%, 0.30%, 
0.46%, and 0.61% at ages 45, 55, 65, and 75, respectively. The corresponding BVL per year values of the 
age-dependent 95th percentiles were 0.52%, 0.77%, 1.05% and 1.45%. Pathological BVL can be assumed if 
an individual BVL per year exceeds these thresholds for a given age. The mean BVL per year determined in 
this longitudinal study was consistent with results from a cross-sectional study that was published 
recently. The cut-off for a pathological BVL per year at age 45 (0.52%) was consistent with the cut-off 
suggested previously to distinguish between physiological and pathological BVL in MS patients. Different 
cut-off values, however, need to be considered when interpreting BVL assessed in cohorts of higher ages.  
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Introduction 
Brain atrophy determined by structural magnetic resonance imaging (MRI) is an increasingly recognized 
measure of degenerative pathology in neurodegenerative disorders including multiple sclerosis (MS). 
Brain volume loss per year (BVL per year) between 0.1% and 0.3% has been reported in young, healthy 
individuals (Takao, et al., 2012). In contrast, MS patients of comparable age show BVL per year that 
typically cluster between 0.50% and 1.35% (Chard and Miller, 2009). Such BVL per year clearly falls 
beyond what seems related to physiological aging and thus may serve as a potential early marker of 
disease progression (Fisniku, et al., 2008, Popescu, et al., 2013). Recently, a cut-off of 0.52% BVL per year 
(with an error rate of 5%) or 0.40% BVL per year (with an error rate of 20%) has been suggested to 
distinguish between physiological and pathological BVL in MS patients (De Stefano, et al., 2016).  
Several cross-sectional (Fjell, et al., 2009, Fjell, et al., 2013, Marcus, et al., 2007, Schippling, et al., 2017, 
Ziegler, et al., 2012), as well as longitudinal studies (Driscoll, et al., 2009, Hedman, et al., 2012, Marcus, et 
al., 2010, Taki, et al., 2011 ), found that BVL critically depends on age, in both, MS patients and healthy 
individuals. A recent study reported age dependent mean BVL per year values in physiological aging 
(Schippling, et al., 2017). However, the data in that study were extrapolated from cross-sectional brain 
volumetry data using a non-parametric fitting approach. As discussed before (Schippling, et al., 2017), 
cross-sectional data allows the determination of mean BVL per year values of a given cohort, but lacks 
estimates of the biological variability (age-dependent standard deviations) of BVL per year values for a 
specific age range. To interpret BVL per year in disease models correctly, it is of utmost importance to do 
so against the background of measurements derived from longitudinal studies in healthy aging 
populations, to allow a correction for physiological aging. The aim of this study was to validate BVL per 
year in healthy individuals that some of the authors of this study previously investigated cross-sectionally 
(Schippling, et al., 2017) using a longitudinal cohort of healthy individuals. We assessed the mean and the 
variability of the BVL per year for each age range. Beyond confirming results of other longitudinal studies 
on physiological aging (Driscoll, et al., 2009,Hedman, et al., 2012,Marcus, et al., 2010,Taki, et al., 2011 ), in 
a large single-scanner cohort, the aim of this study was to provide cut-off values to discriminate 
physiological from pathological BVL in an age-dependent manner.  
 
Methods 
Study participants  
The cohort was selected from a group of asymptomatic, healthy individuals undergoing a brain MRI scan 
as part of an extensive medical prevention program at the Medical Prevention Center (MPCH) in Hamburg, 
Germany. All participants gave written informed consent. The study was approved by the Ethics 
Committee of the Board of Physicians in Hamburg, Germany. Individuals participating in the prevention 
program were included into the final cohort if they had no history of or currently ongoing neurological or 
psychiatric condition, and if there were no structural abnormalities on the brain MRIs according to visual 
inspection by an experienced radiologist (C.G.). Eligible participants  received at least two MRI 
examinations on the same 1.5 Tesla Magnetom Avanto® scanner (Siemens Medical Solutions, Erlangen, 
Germany, software version B15) using the identical 8-channel head coil and identical sequence settings 
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throughout the study. Originally, 119 participants were included in this study. Two of these participants 
were excluded; one participant (age 23.7 years) was more than 10 years younger than the second-
youngest participant of the cohort. Similarly, the second excluded participant (age 88.9 years) was more 
than 5 years older than the second-oldest participant of the cohort.  We excluded these patients to avoid 
non-linear effects in the fitting of the results for the whole cohort. From the remaining 117 participants, 
93 were males and 24 were females and the mean age was 61.9 years (range 37.3–82.6 years). The cohort 
comprised 89 participants with exactly one follow-up scan, 20 participants with 2 follow-up scans, and 8 
participants with more than 2 follow-up scans. Age distribution of the cohort is shown in Figure 1. The 
mean interval time between baseline and the latest follow-up scan was 3.2 years (standard deviation (SD) 
1.54 years, range 2-7 years). 
 
MRI protocol 
The MRI protocol consisted of a 3D T1-weighted magnetization prepared rapid gradient echo (MPRAGE) 
sequence with a repetition time (TR) of 980 ms, echo time (TE) of 2.95 ms, inversion time (TI) of 600 ms, a 
flip angle of 15°, and an isotropic voxel grid of 1 mm. The MPRAGE sequence lasted for approximately 3:10 
minutes. The MPRAGE sequence was applied as a diagnostic sequence as part of a larger protocol that 
included a whole body MRI examination with an angiogram. For the angiogram, a contrast agent 
(Gadovist®) was applied. The MPRAGE sequence analyzed for this study was obtained before contrast 
agent administration. As the scanner is a dedicated examination tool for the prevention program, protocol 
settings, head coil, and software version were kept unchanged throughout the study period. In less than 
1% of the scans the MPRAGE sequence was repeated due to motion artifacts. Regular consistency 
measurements were performed on the scanner as an important part of the regular 3-4 months service 
intervals to ensure no deviation from former measurements. The images analyzed in this study are 
therefore comparable over the whole study period. 
  
Brain volume loss (BVL) with SIENA 
BVL of the whole brain between two time points was quantified using the SIENA method (Smith, et al., 
2002) which is part of the FMRIB Software Library (FSL; http://www.fmrib.ox.ac.uk/fsl). The 
performance of SIENA can differ greatly depending on parameter settings and pre-processing steps 
(Cover, et al., 2014, Popescu, et al., 2012). We used SIENA (Version 5.06) with optimized preprocessing 
parameters. As a first preprocessing step we applied the FSL script “fslreorient2std” to match the 
orientation of all images to that of the standard template image (MNI). In addition, we performed a neck 
removal as recommended (Popescu, et al., 2012). Skull-stripping with the brain extraction tool BET (FSL; 
https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/BET/) was deployed and the SIENA settings were "-B -f 0.2 -m", 
which differ from the default settings. With the configuration described we calculated the BVL (in %) for 
all study participants. For several participants, more than two scans were available. In these cases the BVL 
was calculated for each pair of two consecutive MRI scans. Annualized BVL (BVL per year) was calculated 
for each participant from the slope of the regression line fitted to all BVL measurements for that 
participant. More precisely, if  		denotes the percentage BVL measurement between two time points 
  and 	
, then the participant’s brain volume (denoted by ) will change according to the 
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formula 	
 =  ⋅ (1 − /100). For each participant we then computed a linear regression 
function 	fitting the data	( 	,  	). The final annualized percentage BVL for each study participant 
was then defined as 


: = 100 ⋅ 	( )!(")
( )("! )
 where # is the age at baseline and $ is the age at 
the last follow-up scan. Note, that /%& computed with the formula above is independent from the 
brain volume # at baseline, which was set to 100. In the case of only two available MRI scans (and thus 
only one BVL measurement) the formula reduces to 100 ⋅ 	( )!(')
( )('! )
= '
()*'!()* 
. The latter 
expression is the known formula to annualize BVL measurements (BVL per year).  
 
Statistics 
For the analysis of each participant, age was defined as the mean of the age at baseline and the age at the 
last follow-up scan. Age and BVL per year were tested for differences between males and females with a 
two-sample t-test. We calculated a linear regression function & between age (denoted by ) and 
/%&  for all study participants. Points on the regression line can be interpreted as mean BVL per year 
for a particular age.  For each age we determined the variability of the measurements at that age by a 
sliding window technique. More precisely, for each age + all participants with ages within the interval 
x±15 years were used to compute the age dependent 80th and 95th percentile of the distances from the 
measured BVL per year to the regression line at the corresponding ages (more mathematically:  for each 
age x we computed the percentiles(x) of the numbers	,	-&-./ − ./%&/ ∶ all	3	such	that	+ − 15 ≤
. ≤ + + 15<). For each age we can expect that 5% of the measurements exceed the 95th percentile and 
20% of the measurements exceed the 80th percentile. Therefore, the 95th percentile can be used as a cut-
off for pathological BVL per year with an error probability of 5% and the 80th percentile can be used as a 
cut-off with an error probability of 20%.  
 
Results 
Mean BVL per year was not significantly different between male (0.42% ± 0.37%) and female (0.36%± 
0.35%) participants (p=0.51; Table 1). Mean BVL per year was 0.15%, 0.30%, 0.46%, and 0.61% at ages 
45, 55, 65, and 75, respectively (Table 2 and regression line depicted in Figure 2). In Table 2, columns 
three and four show the 80th and 95th percentiles for BVL per year between ages 45 to 80 years. These 
values can serve as age-dependent cut-offs to distinguish physiological from pathological BVL with 80% 
and 95% specificity, respectively. The cut-offs for a pathological BVL per year (with an error probability of 
5%) were 0.52%, 0.77%, 1.05%, and 1.45% at ages 45, 55, 65, and 75, respectively (Table 2 and Figure 2). 
Figure 2 shows the association of age with measured BVL per year and the resulting 95th percentiles. 
Figure 3 shows example slices of 3D T1-weighted images from a 46-year-old and a 72-year-old 
participant, illustrating the different BVL rates at different ages. 
 
 
 
 
Discussion 
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BVL per year values reported here using SIENA/FSL in a longitudinal cohort of healthy individuals were 
consistent with BVL per year values extrapolated from cross-sectional data that some of the authors of 
this study reported before (Schippling, et al., 2017). Previously, 0.24% BVL per year at age 45 and 0.52% 
at age 70 was determined from cross-sectional data (Schippling, et al., 2017), whereas in this longitudinal 
study we found a BVL per year of 0.15% at age 45 and 0.53% at age 70. We therefore confirmed the 
previous observation that BVL increases concomitantly with age. The baseline MRIs of 29 participants of 
this longitudinal study were part of the data in the above mentioned cross-sectional study (Schippling, et 
al., 2017).   Few other studies did not observe a similar relationship between BVL and aging (Jack, et al., 
2008, Mueller, et al., 1998 , Scahill, et al., 2003). A possible limitation of these studies is the small sample 
size (n≈40). In addition, for longitudinal studies in particular, the methodology applied for the 
determination of BVL impacts greatly on the results (Durand-Dubief, et al., 2012). It is known that 
segmentation based methods usually feature a higher variability than registration based methods 
(Durand-Dubief, et al., 2012). Thus, it is important to measure BVL with a method featuring high accuracy 
and low variability. In this study, BVL was measured with SIENA/FSL which is a registration based 
method (Smith, et al., 2002). This software tool is well established in the assessment of longitudinal BVL 
and features a median error of 0.15% (Smith, et al., 2002). The interval between MRI examinations is 
critical and needs to be sufficiently long, to distinguish between changes due to physiological effects and 
those due to methodological and biological noise. For participants with only one follow-up, we annualized 
BVL values by dividing the value by the length of the interval between scans (which is the same as the 
slope of the regression line through the measurements divided by the scan interval) thereby improving 
the signal-to-noise ratio. The mean scan interval in this study was 3.2 years (range 2-7 years), hence the 
magnitude of the noise level of BVL per year in this study is approximately 0.15%/3.2 = 0.046%. Since the 
estimated noise level of 0.046% is approximately 10 times smaller than the measured effects (mean BVL 
per year is 0.42%) we can conclude that noise or measurement error has only a limited impact on our 
results.  
With increasing age, the BVL per year measurements seem to have more variability (see scatter plot in 
Figure 2). From a biological perspective, a lifetime of influencing (including toxic) factors has accumulated 
in older participants and may impact on the actual brain volume. Also, it cannot be ultimately ruled out 
that in some older participants, subclinical or very early pathological effects impact brain tissue integrity. 
Therefore, determining the physiological BVL and reliably distinguishing it from pathological atrophy 
becomes even more challenging with older age. One aim of our study was to capture this age dependent 
variability by applying a sliding window technique when computing the 80th and 95th percentiles. We used 
a window size of 30 years (± 15 years) which we found to be large enough to capture a sufficient number 
of measurements for each window, while at the same time, small enough to capture the increasing 
variability. At the boundary of the data (age 45 and 80) the sliding window interval contained 54 
measurements while at the center of the data (age 60) the interval contained 96 measurements. An 
alternative approach is to compute constant 80th and 95th percentiles over the whole age range. By doing 
so, the resulting age dependent 95th percentiles are 0.73% per year, 0.88% per year, 1.04% per year, and 
1.19% per year at ages 45, 55, 65, and 75, respectively (the corresponding values with the sliding window 
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technique are shown in Table 2, column 4). The resulting cut-offs using a constant 95th percentile seem to 
overestimate true variability for younger participants and to underestimate it for older individuals.  
As mentioned above, a cut-off of 0.52% per year (error rate 5%) or 0.40% per year (error rate 20%) has 
been suggested based on a cohort of 35 healthy controls (mean age 37 years) to distinguish physiological 
from pathological BVL in MS (De Stefano, et al., 2016). The mean follow-up time in that study was 6.3 
years and the BVL was computed with the same method (SIENA/FSL) as in our study. From this 
longitudinal cohort, we obtain cut-offs of 0.52% per year (error rate of 5%) and 0.33% per year (error 
rate of 20%) for 45-year-old patients which is consistent with the cut-offs proposed in that previous 
study. Our results also clearly show that for older age groups different cut-off values for pathological BVL 
need to be considered (Table 2).   
It is not trivial to establish a sensitive cut-off that is able to discriminate between physiological and 
pathological BVL in MS patients as previously mentioned (Barkhof, 2016, De Stefano, et al., 2016) since the 
overlap between BVL in patients and healthy controls is significant. In particular, not all MS patients 
exhibit pathological brain atrophy. A number of disease (e.g. inflammatory edema, seemingly increasing 
brain volumes) and treatment related factors (e.g. washout of inflammatory edema leading to so-called 
“pseudo-atrophy”) complicate the interpretation of single measures, especially when applied on short-
term repeated MRI scans. Therefore, the increased variability of physiological BVL per year with age adds 
to the complexity of brain volume measures on a single patient level, rendering it difficult to reliably 
distinguish between physiological and pathological BVL. With the cut-offs provided here, it is, however, 
possible to estimate whether or not a measured BVL falls beyond the borders of the physiological range 
with satisfying specificity.  
In contrast to other longitudinal studies on physiological ageing (Driscoll, et al., 2009, Hedman, et al., 
2012, Marcus, et al., 2010, Taki, et al., 2011 ), this study includes a large cohort of healthy participants 
with a broad age range and a sufficiently long follow-up time. Furthermore, we used highly standardized 
MRI acquisitions over several years in a single-scanner setting. To our knowledge, this is the first study 
reporting mean BVL per year values as well as the biological variability of BVL per year in physiological 
aging for a broad age range. However, a possible limitation of this study is the male preponderance of the 
cohort, since particularly in MS, women are more frequently affected. We did not find, however, a 
significant difference in age or BVL per year between gender, the latter being consistent with previous 
publications (Fjell, et al., 2009, Takao, et al., 2012, Tang, et al., 2001). 
Other factors that might have an impact on accelerated atrophy in older age are related to lifestyle, like 
smoking or alcohol consumption, genetics, like apolipoprotein E expression as much as cardiovascular 
risk profiles, like diabetes or hypertension (Enzinger, et al., 2005). Even if biological factors are accounted 
for, methodological factors such as scanner, coil, and protocol changes greatly influence the results of BVL 
measurements. We tried to mitigate these effects by using scans that were acquired on the same MRI 
scanner with the same protocol and settings throughout the study. We used a widely applied software 
package (SIENA), which has been shown to have low test-retest variability (Cover, et al., 2011, Smith, et 
al., 2007). However, we have to emphasize that the provided cut-offs are only valid for results obtained 
using the same method. Finally, the method used here does not provide information on regional volume 
changes. Other methodologies such as Jacobian determinant (Ashburner and Ridgway, 2012) or Statistical 
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Parametric Mapping (Ashburner and Friston, 2000, Muhlau, et al., 2009) should be applied to obtain tissue 
specific cut-off values of BVL.  
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Figure 1. Age distribution (separated for males and females) of the cohort.  
 
 
Figure 2. Association of age and measured brain volume loss (BVL) per year (in %). The dotted line 
represents the 95th percentile. The red area indicates values of abnormal BVL per year since 95% of all 
healthy study participants feature lower BVL per year.  
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Figure 3. Example of axial slices of a 3D T1-weighted image for two participants illustrating different 
brain volume loss (BVL) values. The upper row shows 3D T1-weighted images of a 72-year-old male at 
baseline (A) and after 6.4 years (B) exhibiting a BVL of 3.6% (0.56% per year). The lower row shows 3D 
T1- weighted images of a 46-year-old female at baseline (C) and after 6.5 years (D) showing a BVL of 
0.93% (0.14% per year).  
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Table 1. Age and brain volume loss (BVL) per year for male and female participants. For each participant 
the mean of the age at baseline and the age at the last follow-up scan is reported. Values are given as mean 
± standard deviation.   
 n Age (years) BVL (%) per year  
males 93 62.1 ± 11.2 0.42 ± 0.37 
females 24 61.04 ± 10.7 0.36 ± 0.35 
p-value  0.77 0.51 
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Table 2. Brain volume loss (BVL) per year between 45 and 80 years. Data are given as mean (2nd 
column), 80th percentile (3rd column) and 95th percentile (4th column). The values in the last two columns 
can be used as age-dependent cut-offs for pathological BVL with an error probability of 20% and 5%, 
respectively.  
age 
(years) 
mean BVL 
(%) per year  
Cut-off for pathological BVL (%) per 
year with an error probability of 
20% 5% 
45 0.15 0.33 0.52 
50 0.22 0.38 0.59 
55 0.30 0.43 0.77 
60 0.38 0.50 0.91 
65 0.46 0.60 1.05 
70 0.53 0.72 1.27 
75 0.61 0.80 1.45 
80 0.69 0.93 1.55 
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Estimates of age-dependent cut-offs for pathological brain 
volume loss using SIENA/FSL – A longitudinal brain 
volumetry study in healthy adults 
 
Highlights: 
• Brain volume loss (BVL) assessed by MRI is a relevant marker of brain tissue damage.  
• BVL rates were assessed in cohort of 119 healthy subjects longitudinally.  
• BVL means and variability by age was computed using a sliding window technique.  
• A list of age-dependent cut-offs for pathological BVL is provided.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Disclosures 
Roland Opfer and Ann-Christin Ostwaldt are employees by jung diagnostics GmbH, Hamburg, Germany 
S. Schippling is supported by the Clinical Research Priority Program of the University of Zurich and the 
Swiss Multiple Sclerosis Society. He has received research grants from Novartis and Sanofi Genzyme, and 
consultancy and speaker fees from Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva. 
 P. Manogaran and C. Walker-Egger received travel support from Sanofi Genzyme and Merck Sereno..  
N. de Stefano has received honoraria and consultation fees from Merck Serono S.A., Teva Pharmaceutical 
Industries, Novartis Pharma AG, BayerSchering AG, Sanofi-Aventis and Serono Symposia International 
Foundation.  
MP. Sormani received consulting fees from Biogen Idec, Merck Serono, Teva, Genzyme, Roche, Novartis, 
GeNeuro and Medday. 
There was no financial support related to the manuscript 
 
We confirm that the manuscript is not under review at another journal have not been previously 
published.  
All subjects included in the study gave written informed consent. The study was approved by the Ethics 
Committee of the Board of Physicians in Hamburg, Germany. 
We confirm that all authors had access to the full dataset and were involved in all stages of development 
and finalization of the manuscript.  
 
 
 
 
